Oncology and Hematology

17-32 of 664

• 

  RestartResume

  Epic Aura for CRC Screening: A Real-World Perspective

  RestartResume

  Epic Aura for CRC Screening: A Real-World Perspective

  Clinician's Roundtable

  Epic Aura for CRC Screening: A Real-World Perspective

  Natalia Usoltseva MD, FACP, MHA

  • 

    

    Natalia Usoltseva MD, FACP, MHA

• 

  RestartResume

  Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data

  RestartResume

  Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data

  Project Oncology®

  Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data

  Charles Turck, PharmD, BCPS, BCCCP; Petros Grivas, MD, PhD

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Petros Grivas, MD, PhD

• 

  RestartResume

  Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors

  RestartResume

  Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors

  CME/CE

  Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors

  Enriqueta Felip, MD; Kristi Orbaugh, MSN, RNP, AOCN

  0.25 credits

  • 

    

    Enriqueta Felip, MD

  • 

    

    Kristi Orbaugh, MSN, RNP, AOCN

  0.25 credits

• 

  RestartResume

  EGFR-Mutated NSCLC With Brain Metastases: Navigating ADC Treatment Decisions

  RestartResume

  EGFR-Mutated NSCLC With Brain Metastases: Navigating ADC Treatment Decisions

  MinuteCE®

  EGFR-Mutated NSCLC With Brain Metastases: Navigating ADC Treatment Decisions

  Benjamin Levy, MD; Melin Khandekar, MD, PhD

  1.00 program credit

  • 

    

    Benjamin Levy, MD

  • 

    

    Melin Khandekar, MD, PhD

  1.00 program credit

• 

  MinuteCE®

  Inside the Decision: Case-Based Navigation of Brain Metastases in Breast and Lung Cancer

  Barbara O'Brien, MD; Benjamin Levy, MD

  1.00 credit 6 episodes

  • 

    

    Barbara O'Brien, MD

  • 

    

    Benjamin Levy, MD

  • 

    

    Melin Khandekar, MD, PhD

  • 

    

    Nadia Harbeck, MD, PhD

  1.00 credit 6 episodes

• 

  RestartResume

  Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC 

  RestartResume

  Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC 

  MinuteCE®

  Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC 

  Benjamin Levy, MD; Melin Khandekar, MD, PhD

  1.00 program credit

  • 

    

    Benjamin Levy, MD

  • 

    

    Melin Khandekar, MD, PhD

  1.00 program credit

• 

  RestartResume

  HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era

  RestartResume

  HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era

  MinuteCE®

  HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era

  Barbara O'Brien, MD; Nadia Harbeck, MD, PhD

  1.00 program credit

  • 

    

    Barbara O'Brien, MD

  • 

    

    Nadia Harbeck, MD, PhD

  1.00 program credit

• 

  RestartResume

  Managing Brain Metastases Through Multidisciplinary Team Collaboration

  RestartResume

  Managing Brain Metastases Through Multidisciplinary Team Collaboration

  MinuteCE®

  Managing Brain Metastases Through Multidisciplinary Team Collaboration

  Benjamin Levy, MD

  1.00 program credit

  • 

    

    Benjamin Levy, MD

  1.00 program credit

• 

  RestartResume

  Brain Metastases Management: From Detection to Multidisciplinary Care

  RestartResume

  Brain Metastases Management: From Detection to Multidisciplinary Care

  MinuteCE®

  Brain Metastases Management: From Detection to Multidisciplinary Care

  Barbara O'Brien, MD

  1.00 program credit

  • 

    

    Barbara O'Brien, MD

  1.00 program credit

• 

  RestartResume

  First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases

  RestartResume

  First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases

  MinuteCE®

  First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases

  Barbara O'Brien, MD; Nadia Harbeck, MD, PhD

  1.00 program credit

  • 

    

    Barbara O'Brien, MD

  • 

    

    Nadia Harbeck, MD, PhD

  1.00 program credit

• 

  RestartResume

  Decision in Context: A Practical Framework for Sequencing Systemic and CNS Therapies in Brain Metastases

  RestartResume

  Decision in Context: A Practical Framework for Sequencing Systemic and CNS Therapies in Brain Metastases

  CME/CE

  Decision in Context: A Practical Framework for Sequencing Systemic and CNS Therapies in Brain Metastases

  Barbara O'Brien, MD

  0.25 credits

  • 

    

    Barbara O'Brien, MD

  0.25 credits

• 

  CME/CE In-Person & Virtual Event

  Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer

  May 30, 2026
  Chicago, Illinois

  1.50 credits

• 

  RestartResume

  Choosing the Right Treatment in ALK and ROS1-Positive NSCLC

  RestartResume

  Choosing the Right Treatment in ALK and ROS1-Positive NSCLC

  Project Oncology®

  Choosing the Right Treatment in ALK and ROS1-Positive NSCLC

  Raghava Reddy Induru, MD

  • 

    

    Raghava Reddy Induru, MD

• 

  RestartResume

  Real-World Cases in Squamous Cell Carcinoma of the Anal Canal Care

  RestartResume

  Real-World Cases in Squamous Cell Carcinoma of the Anal Canal Care

  Project Oncology®

  Real-World Cases in Squamous Cell Carcinoma of the Anal Canal Care

  Brian P. McDonough, MD, FAAFP; Madison Conces, MD

  • 

    

    Brian P. McDonough, MD, FAAFP

  • 

    

    Madison Conces, MD

  • 

    

    Midhun Malla, MD

• 

  RestartResume

  Getting Biomarker Testing Right in Non-Small Cell Lung Cancer Care

  RestartResume

  Getting Biomarker Testing Right in Non-Small Cell Lung Cancer Care

  Project Oncology®

  Getting Biomarker Testing Right in Non-Small Cell Lung Cancer Care

  Raghava Reddy Induru, MD

  • 

    

    Raghava Reddy Induru, MD

• 

  RestartResume

  Making Mechanism-Based Treatment Decisions in cGVHD

  RestartResume

  Making Mechanism-Based Treatment Decisions in cGVHD

  Project Oncology®

  Making Mechanism-Based Treatment Decisions in cGVHD

  Brian P. McDonough, MD, FAAFP; Alicia Lieberman, MD, MS

  • 

    

    Brian P. McDonough, MD, FAAFP

  • 

    

    Alicia Lieberman, MD, MS

• Previous
• 1
• 2
• 3
• 4
• …
• 41
• 42
• Next